Abacus Global responds to ‘false and misleading short attack’

Abacus Global (ABL) Management provided a response to last week’s “false and misleading short attack.” The company said, “Our shareholders have been subjected to a false and uninformed short attack. The short seller’s report published on June 4, 2025 makes two key allegations: first, that Abacus relies too heavily on a single life expectancy provider, and second, that this reliance has significantly inflated our balance sheet valuation. Both are incorrect. Abacus remains resolute in our process, valuation methodology, and the benefit we provide to both policyholders and investors. Our market coverage analysts share this sentiment as well, and have supported our process with published statements and maintained buy, outperform, or overweight ratings on our stock…In addition to research analyst support, our auditor Grant Thornton has also affirmed our mark-to-market valuation approach for the policies we hold on our balance sheet, and has not seen any reason to revise that opinion since the publication of the short report. It is important to note that the report contained a misleading statement attributed to a Grant Thornton UK CEO. The UK-based company is a separate legal entity from our auditor, Grant Thornton US, and each firm operates independently and manages its own affairs…In summary, Abacus strongly refutes the misleading and incorrect claims made by the short seller. We are supported by outside market research analysts, third-party actuarial firms, our auditor, and our transparent accounting methodology used in fair market reporting driven by mark-to-market valuations. Abacus is a leading alternative asset manager, market maker, technology company, and growing private wealth manager. We will not allow this distraction to slow our growth and expansion.”